Bellerophon Therapeutics

Bellerophon Therapeutics, Inc. operates as a clinical-stage biotherapeutics company. The Company develops molecules deployed delivery systems to treat cardiopulmonary diseases.
Bellerophon Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Bellerophon Therapeutics balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Bellerophon Therapeutics cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Bellerophon Therapeutics multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Bellerophon Therapeutics profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Bellerophon Therapeutics assets
Bellerophon Therapeutics cash flows

Bellerophon Therapeutics shares

TickerNameTypeNominal valueISINPrice
BLPH:USBellerophon TherapeuticsCommon share-US0787711029$0.036
Bellerophon Therapeutics news
11.05.2022
Bellerophon Therapeutics' GAAP loss for 3 months of 2022 was $5.641 million, up 3.3% from $5.461 million in the prior year.
Source: investors.bellerophon.com pictogram investors.bellerophon.com
Pictogram next
01.04.2022
Bellerophon Therapeutics' GAAP loss for 2021 was $17.756 million, down 28.2% from $24.728 million the previous year.
Source: investors.bellerophon.com pictogram investors.bellerophon.com
Pictogram next
15.11.2021
Bellerophon Therapeutics' GAAP loss for 9M 2021 was $13.484 million, down 19.4% from $16.723 million in the prior year.
Source: investors.bellerophon.com pictogram investors.bellerophon.com
Pictogram next
05.08.2021
Bellerophon Therapeutics' GAAP loss for 6 months of 2021 was $8.85 million, up 0.7% from $8.79 million in the prior year.
Source: investors.bellerophon.com pictogram investors.bellerophon.com
Pictogram next
All Bellerophon Therapeutics news
General information
Company nameBellerophon Therapeutics
SectorHealth Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Supplies
Business address184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Mailing address184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Websitewww.bellerophon.com
Information disclosurewww.sec.gov